December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
Year: 2025
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...